Agonistic autoantibodies (AAs) directed against receptors of the sympathetic nervous system and the renin–angiotensin system have been suggested to contribute to cardiovascular and renal disease, in particular hypertension, preeclampsia, and graft failure in kidney transplantation patients. Consequently, they are now also being studied as biomarker for these conditions. This commentary summarizes our current understanding of these AAs, critically discussing whether they truly act as agonist, and focusing on the wide array of assays that are currently used for their quantification.
Skip Nav Destination
Commentary| January 11 2018
Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker?
Rugina Neuman, A.H. Jan Danser; Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker?. Clin Sci (Lond) 16 January 2018; 132 (1): 127–130. doi: https://doi.org/10.1042/CS20171485
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article